SCOTT M. LIPPMAN, M.D.
Osteopathic Medicine at Holcombe Blvd, Houston, TX
License number
Texas H4987
Category
Osteopathic Medicine
Type
Medical Oncology
Address
Address
1515 Holcombe Blvd, Houston, TX 77030
Phone
(713) 792-6161
(713) 792-2991
(713) 792-2991
Personal information
See more information about SCOTT M. LIPPMAN at radaris.comName
Address
Phone
106 Sandalwood Dr, Houston, TX 77024
2420 Locke Ln, Houston, TX 77019
1616 Fountain View Dr, Houston, TX 77057
Houston, TX
Organization information
See more information about SCOTT M. LIPPMAN at bizstanding.comM D Anderson Cancer Center - Scott M Lippman MD
1500 Holcombe Blvd #432, Houston, TX 77030
Categories:
Oncology Physicians & Surgeons
Site:
Phone:
(713) 745-6659 (Phone)
Professional information
See more information about SCOTT M. LIPPMAN at trustoria.com
Scott M Lippman, Houston TX
Scott M Lippman, Houston TX
Specialties:
Oncologist
Address:
1515 Holcombe Blvd, Houston, TX 77030
Education:
Johns Hopkins University, School of Medicine - Doctor of Medicine
University Medical Center - Fellowship - Hematology and Oncology (Internal Medicine)
Stanford Hospital & Clinics - Fellowship - Hematology
Los Angeles County Harbor-UCLA Medical Center - Residency - Internal Medicine
Johns Hopkins Hospital - Internship - Internal Medicine
University Medical Center - Fellowship - Hematology and Oncology (Internal Medicine)
Stanford Hospital & Clinics - Fellowship - Hematology
Los Angeles County Harbor-UCLA Medical Center - Residency - Internal Medicine
Johns Hopkins Hospital - Internship - Internal Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Hematology (Internal Medicine), American Board of Internal Medicine Sub-certificate in Oncology (Internal Medicine)
Dr. Scott M Lippman, La Jolla CA - MD (Doctor of Medicine)
Dr. Scott M Lippman, La Jolla CA - MD (Doctor of Medicine)
Specialties:
Hematology, Medical Oncology, Oncology
Address:
3855 Health Sciences Dr, La Jolla 92093
(858) 822-1222 (Phone)
1515 Holcombe Blvd SUITE 432, Houston 77030
(713) 792-6161 (Phone), (713) 745-2012 (Fax)
1515 Holcombe Blvd, Houston 77030
MD ANDERSON CANCER CENTER
1515 Holcombe Blvd, Houston 77030
(713) 792-2121 (Phone), (713) 794-5492 (Fax)
(858) 822-1222 (Phone)
1515 Holcombe Blvd SUITE 432, Houston 77030
(713) 792-6161 (Phone), (713) 745-2012 (Fax)
1515 Holcombe Blvd, Houston 77030
MD ANDERSON CANCER CENTER
1515 Holcombe Blvd, Houston 77030
(713) 792-2121 (Phone), (713) 794-5492 (Fax)
Certifications:
Hematology, 1988, Internal Medicine, 1987, Medical Oncology, 1989
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
3855 Health Sciences Dr, La Jolla 92093
1515 Holcombe Blvd SUITE 432, Houston 77030
1515 Holcombe Blvd, Houston 77030
MD ANDERSON CANCER CENTER
1515 Holcombe Blvd, Houston 77030
The University of Texas M.D. Anderson Cancer Center
1515 Holcombe Blvd, Houston 77030
1515 Holcombe Blvd SUITE 432, Houston 77030
1515 Holcombe Blvd, Houston 77030
MD ANDERSON CANCER CENTER
1515 Holcombe Blvd, Houston 77030
The University of Texas M.D. Anderson Cancer Center
1515 Holcombe Blvd, Houston 77030
Education:
Medical School
Johns Hopkins Univ Sch Of Med
Graduated: 1981
The Johns Hopkins Hospital
Los Angeles County Harbor - UCLA Medical Center
Stanford Med Ctr
U Ariz Hlth Scis Ctr
Johns Hopkins Univ Sch Of Med
Graduated: 1981
The Johns Hopkins Hospital
Los Angeles County Harbor - UCLA Medical Center
Stanford Med Ctr
U Ariz Hlth Scis Ctr
Scott Michael Lippman, Houston TX
Scott Michael Lippman, Houston TX
Specialties:
Internal Medicine, Hematology, Medical Oncology, Hematology & Oncology, Hematology
Work:
MD Anderson Cancer Ctr
1515 Holcombe Blvd, Houston, TX 77030
1515 Holcombe Blvd, Houston, TX 77030
Education:
Johns Hopkins University (1981)
Biomarkers For Response To Tyrosine Kinase Pathway Inhibitors In Cancer
Biomarkers For Response To Tyrosine Kinase Pathway Inhibitors In Cancer
US Patent:
2013023, Sep 5, 2013
Filed:
Feb 4, 2013
Appl. No.:
13/758728
Inventors:
Ignacio I. WISTUBA - Houston TX, US
Monique B. NILSSON - Sugar Land TX, US
Lauren A. BYERS - Houston TX, US
Ximing TANG - Houston TX, US
Fei YANG - Houston TX, US
Edward KIM - Houston TX, US
Anne S. TSAO - Houston TX, US
Scott M. LIPPMAN - Houston TX, US
Waun Ki HONG - Houston TX, US
Roy S. HERBST - Houston TX, US
Monique B. NILSSON - Sugar Land TX, US
Lauren A. BYERS - Houston TX, US
Ximing TANG - Houston TX, US
Fei YANG - Houston TX, US
Edward KIM - Houston TX, US
Anne S. TSAO - Houston TX, US
Scott M. LIPPMAN - Houston TX, US
Waun Ki HONG - Houston TX, US
Roy S. HERBST - Houston TX, US
Assignee:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM - Austin TX
International Classification:
G01N 33/74, A61K 39/395, A61K 31/506, A61K 31/4439, C12Q 1/68, A61K 31/4045
US Classification:
4241331, 435 723, 435 611, 514414, 51425218, 514338
Abstract:
Copy number gains detected in tumors and associated with drug sensitivity and resistance in vivo and in vitro can be used as biomarkers to select, predict and monitor drug treatment outcomes in cancer patients treated with tyrosine kinase inhibitors. Methods to identify patients with NSCLC or other malignancies who are more likely to benefit from tyrosine kinase inhibitors such as VEGF or VEGFR inhibitors when used either as monotherapy or in combination with other therapies such as chemotherapy or EGFR inhibitors, and who are in the advanced stages of disease and/or who have undergone adjuvant therapy are also provided herein.